<DOC>
	<DOC>NCT01716559</DOC>
	<brief_summary>This observational, prospective, multicenter study will evaluate the treatment response rate and the safety of NeoRecormon (epoetin beta) in anemic patients with non-myeloid malignancy. In addition to NeoRecormon, patients receive chemotherapy for their malignancy. Data will be collected for 16 weeks.</brief_summary>
	<brief_title>An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy</brief_title>
	<detailed_description />
	<criteria>Adult patients, &gt;/=18 years of age Presence of solidtumor or nonmyeloid malignancy Patients receiving chemotherapy Eastern Cooperative Oncology Group (ECOG) Performance status 02 Patients require NeoRecormon Hypersensitivity to the drug Uncontrolled hypertension Female patients if pregnant and/or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>